Tesamorelin FDA Approval Status February 2026

Tesamorelin FDA Approval Status February 2026. Tesamorelin (Egrifta) FDA approval dates, Phase 1 and Phase 3 trial dates, FDA label indications, latest research 2025-2026, and tesamorelin availability 2026. RESEARCH CONTEXT NOTICE: This article discusses compounds available for laboratory and research use only. All efficacy data referenced comes from published clinical trials and is provided for educational purposes. These products are not intended for human consumption. PeptideStack does not provide medical advice. Key Takeaways Tesamorelin IS FDA-approved — Unlike BPC-157 or TB-500, tesamorelin has full FDA approval under the brand name Egrifta Approved indication: HIV-associated lipodystrophy (reduction of excess abdominal visceral adipose tissue) Original approval: November 2010 by Theratechnologies Inc. New Egrifta WR formulation: Approved March 25, 2025 (tesamorelin F8, ready-to-use formulation) Active clinical trials: NAFLD/MASH (metabolic liver disease) and cognitive function studies ongoing Research-grade tesamorelin: Available for laboratory use separate from prescription Egrifta Researchers frequently ask about tesamorelin FDA approval status when investigating growth hormone-releasing hormone (GHRH) analogs. Unlike most peptides in the research market, tesamorelin stands out as one of the few compounds with actual FDA approval for a specific therapeutic indication — for the complete list of approved peptide drugs, see our FDA approved peptides list 2026 . For the exact question is tesamorelin FDA approved , the answer is yes: prescription tesamorelin is FDA-approved under the Egrifta brand family for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That approval does not extend to general weight loss, bodybuilding, anti-aging, or research-use tesamorelin products. For tesamorelin latest research 2025 2026 and tesamorelin recent studies 2024 2025 2026 searches, the main update is not a new broad approval: it is the continuing clinical interest in visceral adipose tissue reduction, liver fat/metabolic endpoints, and newer Egrifta formulation history. The original tesamorelin FDA approval date remains November 10, 2010. This comprehensive guide covers tesamorelin's complete regulatory history, its mechanism of action, ongoing clinical trials, and how it compares to other GHRH peptides like sermorelin and CJC-1295. What Is Tesamorelin? Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog. It's a modified version of the human GHRH(1-44) peptide, stabilized for therapeutic use. Understanding the tesamorelin mechanism of action is essential for researchers working with GH axis compounds. Chemical Identity Property Value Full Name Tesamorelin acetate Type GHRH analog (Growth Hormone-Releasing Hormone) Amino Acids 44 amino acids Molecular Weight ~5135 Da Modification Trans-3-hexenoic acid addition at N-terminus Brand Name Egrifta (Theratechnologies Inc.) CAS Number 218949-48-5 Mechanism of Action Tesamorelin works by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland. This binding triggers the natural production and release of endogenous growth hormone (GH), rather than supplying exogenous GH directly. Key mechanistic features: Pulsatile GH release: Maintains natural GH secretion patterns rather than constant elevation Feedback preservation: Does not override normal hypothalamic-pituitary feedback loops IGF-1 elevation: Secondary increase in insulin-like growth factor-1 (IGF-1) through hepatic stimulation Lipolytic effects: Documented reduction in visceral adipose tissue (VAT) in clinical trials Tesamorelin FDA Approval History The Egrifta FDA approval timeline represents one of the few success stories for peptide therapeutics reaching market authorization. Here's the complete regulatory history: FDA Approval Timeline Date Event Details November 10, 2010 Original FDA Approval Egrifta approved for HIV-associated lipodystrophy (reduction of excess abdominal fat in HIV-infected patients with lipodystrophy) September 2019 Egrifta SV Approval Date Single-vial reformulation approved (simplified reconstitution vs. original two-vial system); Egrifta SV launched commercially in 2020 March 25, 2025 Egrifta WR (tesamorelin F8) Approval Ready-to-use formulation approved — no reconstitution required, improved patient convenience Approved Indication Tesamorelin (Egrifta) is specifically FDA-approved for: Indication: Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy HIV-associated lipodystrophy is a metabolic condition causing abnormal fat distribution, particularly visceral adipose tissue (VAT) accumulation around abdominal organs. This is distinct from subcutaneous fat and carries cardiovascular and metabolic risks. The official tesamorelin FDA label (prescribing information for Egrifta and Egrifta WR) reflects tesamorelin availability in 2026 through Theratechnologies, with no generic competition on market. If you are trying to understand the practical response window rather than just the approval history, read our How Long Does Tesamorelin Take to Work? guide. It breaks down the published timing data and explains why most headline tesamorelin outcomes are discussed over weeks to months. Manufacturer Information Theratechnologies Inc. (Montreal, Canada) holds the FDA approval and markets Egrifta in the United States. The company specializes in specialty pharmaceuticals for HIV and related conditions. Current FDA Status February 2026 For researchers asking " is tesamorelin FDA approved " — the answer is unequivocally YES , but with important distinctions: FDA Status Summary Question Answer Is tesamorelin FDA approved? YES — Approved as Egrifta Approved indication? HIV-associated lipodystrophy only Prescription required? YES for Egrifta brand product DEA Schedule? Not a controlled substance Current formulations? Egrifta SV (lyophilized) and Egrifta WR (ready-to-use) Generic available? No — patent protection ongoing Off-Label vs. Approved Use While tesamorelin has FDA approval, it's important to understand the regulatory framework: On-label (approved): Prescription Egrifta for HIV-associated lipodystrophy Off-label: Any use outside the approved indication (physicians may prescribe off-label, but this is not FDA-endorsed) Research use: Laboratory-grade tesamorelin for investigational purposes Compounding Regulations Because tesamorelin IS FDA-approved (unlike BPC-157 or TB-500), compounding rules differ. Under FDA regulations, compounding of approved drugs is generally restricted to patient-specific prescriptions from licensed pharmacies, not bulk manufacturing of "research chemicals." This is an important distinction from research peptides that have no FDA approval — those compounds exist in a different regulatory category entirely. Tesamorelin Clinical Trials Status Beyond its approved indication, tesamorelin clinical trials are investigating several additional applications. Researchers tracking peptide clinical trial news should note these ongoing studies: NAFLD/NASH Research The most significant ongoing research involves tesamorelin NAFLD (nonalcoholic fatty liver disease) studies: Rationale: Tesamorelin's documented reduction of visceral adipose tissue may benefit hepatic fat accumulation Key studies: Multiple trials have evaluated tesamorelin's effects on liver fat content in HIV and non-HIV populations Published findings (2024-2025): Studies in JAMA Internal Medicine and Hepatology have documented reductions in hepatic fat fraction Latest tesamorelin research 2025-2026: Recent studies from 2024-2026 continue to evaluate hepatic fat reduction in non-HIV NAFLD/MASH populations, with new analyses examining long-term durability of VAT reduction Cognitive Function Studies Research has explored tesamorelin's effects on cognitive function, particularly in HIV patients where cognitive impairment is common: GH/IGF-1 axis involvement in neuroprotection Studies examining memory and executive function outcomes Ongoing investigation of mechanisms beyond metabolic effects Body Composition Research As a tesamorelin growth hormone analog, research continues into body composition effects: Trunk fat reduction Lipid profile improvements Metabolic marker changes ClinicalTrials.gov Listings Researchers can search ClinicalTrials.gov for "tesamorelin" to find current and completed studies. Unlike BPC-157 (which has zero registered US trials), tesamorelin has an extensive clinical trial history supporting its FDA-approved status. The first tesamorelin human trials (Phase 1) began in the early 2000s, with Phase 3 trial dates spanning 2005-2008 (Study LIPO-010 Phase 3 completed 2008), leading to the November 2010 approval. Tesamorelin vs Other GHRH Peptides Researchers often compare tesamorelin to other GHRH-related compounds. Here's how tesamorelin vs sermorelin and other GHRH peptides compare: GHRH Peptide Comparison Table Property Tesamorelin Sermorelin CJC-1295 (No DAC) CJC-1295 DAC FDA Status ✅ FDA Approved (Egrifta) ❌ Previously approved, now discontinued ❌ Not approved ❌ Not approved Amino Acids 44 (modified GHRH) 29 (GHRH 1-29) 29 + modifications 29 + Drug Affinity Complex Half-Life ~26-38 minutes ~10-20 minutes ~30 minutes ~6-8 days Mechanism GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist (extended) Clinical Trial Data Extensive (Phase 3 completed) Limited (older studies) Limited (Phase 1/2) Limited Primary Research Use Lipodystrophy, NAFLD, body composition GH deficiency research GH axis research Extended GH release research Key Differentiators Tesamorelin's advantages: Only GHRH analog with current FDA approval Extensive Phase 3 clinical trial data Documented efficacy for visceral fat reduction Well-characterized safety profile from prescription use Sermorelin note: Previously FDA-approved (1997) for pediatric growth hormone deficiency but discontinued by manufacturers — no longer available as a prescription product in the US. For detailed comparison of GH-related peptides, see our CJC-1295 vs Ipamorelin research guide . Researchers may also want to review the Ipamorelin FDA Approval Status to understand why this closely related GHRP has not achieved similar regulatory approval. Research Applications Tesamorelin research applications extend across multiple domains for investigators with appropriate credentials: Body Composition Research Visceral adipose tissue (VAT) studies Trunk fat distribution analysis Metabolic rate investigations GH Axis Studies GHRH receptor binding research Pituitary function assessment IGF-1 pathway investigations Metabolic Research Lipid metabolism studies Hepatic fat research (NAFLD models) Glucose metabolism investigations Need help with reconstitution math for your research? Use our free Peptide Reconstitution Calculator to determine concentration and dosage per injection. Combination Research Some researchers investigate tesamorelin in combination with GHRP (Growth Hormone-Releasing Peptide) compounds like Ipamorelin to study comprehensive GH axis stimulation: Frequently Asked Questions Is tesamorelin FDA approved? Yes. Tesamorelin is FDA-approved under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Original approval was November 2010, with updated formulations (Egrifta SV and Egrifta WR) approved subsequently. What is tesamorelin used for? The FDA-approved indication is HIV-associated lipodystrophy — specifically, reducing visceral adipose tissue accumulation. Research applications include body composition studies, NAFLD investigation, and GH axis research. How does tesamorelin compare to sermorelin? Tesamorelin is a 44-amino acid GHRH analog with current FDA approval. Sermorelin is a 29-amino acid GHRH analog that was previously FDA-approved but has been discontinued. Tesamorelin has more extensive clinical trial data and documented efficacy for visceral fat reduction. Is tesamorelin a controlled substance? No. Tesamorelin is not a DEA-scheduled controlled substance. However, prescription Egrifta requires a valid prescription. Research-grade tesamorelin 10mg is available for laboratory use. What is the tesamorelin compounding status? Because tesamorelin has FDA approval (unlike BPC-157 or TB-500), compounding regulations differ. Generally, compounding of FDA-approved drugs is restricted to patient-specific prescriptions from licensed compounding pharmacies, not bulk manufacturing. When did tesamorelin's first human clinical trial begin? Tesamorelin (originally coded TH9507 ) entered its first human clinical trial in the early 2000s, with Phase 1 pharmacokinetic and safety studies conducted by Theratechnologies beginning around 2001–2003 . Phase 2 dose-ranging trials followed in 2004–2006, and the pivotal Phase 3 trials (studies LIPO-010-05 and LIPO-010-06) ran from 2006 to 2009 , forming the efficacy basis for the November 2010 FDA approval. What is the tesamorelin Phase 1 trial date? Tesamorelin's Phase 1 clinical trial date traces to the early 2000s under developer Theratechnologies (compound code TH9507). These early safety and pharmacokinetic studies preceded Phase 2 dose-ranging work in 2004–2006 and the Phase 3 pivotal trials that began in 2006. What are the FDA-approved indications for tesamorelin in 2026? As of 2026, the sole FDA-approved indication for tesamorelin (Egrifta, Egrifta SV, Egrifta WR) is the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy . No additional indications have been approved beyond HIV-associated lipodystrophy, though ongoing research continues into NAFLD, cognitive function, and other metabolic applications. Is "tesa" the same as tesamorelin? Yes — "tesa" is a common shorthand researchers use for tesamorelin. Other frequent misspellings include tesamoreline and tesamorellin ; all refer to the same 44-amino acid GHRH analog (TH9507) sold under the brand names Egrifta, Egrifta SV, and Egrifta WR. What is Egrifta WR and what is the Egrifta WR approval date? Egrifta WR (tesamorelin F8) is the newest tesamorelin formulation. The Egrifta WR FDA approval date is March 25, 2025 . It's a ready-to-use formulation that doesn't require reconstitution, improving convenience compared to the original lyophilized Egrifta and Egrifta SV versions. Does tesamorelin require refrigeration? Prescription Egrifta requires refrigeration. Research-grade lyophilized tesamorelin should be stored at -20°C for long-term stability, with reconstituted solutions refrigerated at 2-8°C. Conclusion The tesamorelin FDA approval status makes it unique among GHRH peptides — it's one of the few compounds in this class with full regulatory approval and extensive clinical trial documentation. From its original 2010 approval through the 2025 Egrifta WR formulation, tesamorelin has established a clear regulatory pathway. For readers asking tesamorelin latest research 2024 2025 2026 , tesamorelin FDA approval indications 2026 , or tesamorelin FDA approval date Egrifta , the approved indication remains HIV-associated lipodystrophy, with the original Egrifta approval in 2010 and formulation updates afterward. For researchers, this means: Published Phase 3 trial data available for reference Well-characterized safety profile from prescription use Ongoing clinical trials for additional indications (NAFLD, cognitive function) Clear differentiation from research-only peptides like BPC-157 or TB-500 For comprehensive information on FDA-approved peptides across all therapeutic categories, see our FDA Approved Peptides List 2026 guide. References U.S. Food and Drug Administration. Egrifta (tesamorelin) prescribing information. FDA Label U.S. Food and Drug Administration. Drugs@FDA: Egrifta approval history and supplements (NDA 022505). Drugs@FDA Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab . 2010;95(9):4291-304. PubMed Stanley TL, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis . 2012;54(11):1642-51. PubMed Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV . 2019;6(12):e821-e830. PubMed ClinicalTrials.gov. Tesamorelin clinical trial registry search. clinicaltrials.gov U.S. Food and Drug Administration. Egrifta WR (tesamorelin F8) approval announcement (March 2025). fda.gov PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, shipping policy, refund policy, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.